First-Line Pharmacological Treatments for Postpartum Hemorrhage (PPH)
Oxytocin is the first-line pharmacological treatment for postpartum hemorrhage (PPH), followed by tranexamic acid (TXA) which should be administered within 3 hours of birth for all women with clinically diagnosed PPH. 1, 2
Primary Treatment Algorithm
First-Line Treatment
Oxytocin:
Tranexamic Acid (TXA):
- Administer early (within 3 hours of birth) at a fixed dose of 1g IV over 10 minutes 2
- A second dose of 1g IV should be given if bleeding continues after 30 minutes or restarts within 24 hours 2
- Strongly recommended by WHO for all cases of PPH regardless of cause (uterine atony, genital tract trauma, etc.) 2
- Effectiveness decreases by 10% for every 15-minute delay in administration 1
Second-Line Treatment (if bleeding persists after 30 minutes)
Prostaglandins (if oxytocin fails):
Ergot Alkaloids:
Important Clinical Considerations
Timing and Efficacy
- Early intervention is critical - TXA should be given within 3 hours of birth, with efficacy decreasing by 10% every 15 minutes 2, 1
- Oxytocin should be administered immediately upon diagnosis of PPH 3
Combination Therapy
- Combined therapy rather than oxytocin alone may be more effective for preventing ongoing PPH 8
- If oxytocin fails to control bleeding, add second-line agents within 30 minutes of PPH diagnosis 3
Mechanical Interventions
- Intrauterine balloon tamponade should be considered if pharmacological management fails 1, 3
- Manual uterine massage should be performed alongside pharmacological treatment 3
Blood Product Management
- Target hemoglobin levels should be maintained above 8 g/dL 1
- Maintain fibrinogen levels above 2 g/L 1, 3
- Consider fresh frozen plasma after 4 units of packed red blood cells 1
Common Pitfalls to Avoid
Delayed TXA administration: TXA must be given within 3 hours of birth; after this timeframe it may be harmful 2
Overreliance on a single agent: Failure to escalate to second-line agents when oxytocin is ineffective within 30 minutes 3
Inadequate dosing: Using subtherapeutic doses of uterotonics due to concerns about side effects 7
Ignoring contraindications: Methylergonovine and carboprost should be avoided in patients with certain cardiovascular conditions 6
Hypothermia: Failure to prevent and treat hypothermia, which worsens coagulopathy; warm infusion solutions and blood products 3
Delayed surgical intervention: Persistent bleeding despite pharmacological management requires timely consideration of surgical options 9